cor2ed
engage checkpoint medical linkedin twitter
bg

Expert Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice

Expert Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice

On-demand video replay and slide set now available

On-demand video replay and slide set now available

Prof. Fred Saad, Assoc. Prof. Tanya Dorff, Prof. Gerhardt Attard, Prof. Neeraj Agarwal

In our recent Expert Knowledge Share, world-renowned experts discussed case studies, reviewed the latest data and shared their views. The on-demand video replay and slide set are available below. Accredited e-learning programme coming soon.

 

Clinical takeaways:

 

  • PARP inhibitors are an important part of the treatment strategy for mCRPC patients
  • mCRPC patients who harbour HRR mutations benefit from PARPi monotherapy following progression on prior novel hormonal agents
  • Treatment with PARP inhibitors plus novel hormonal agents can provide combination benefits in mCRPC patients with or without HRR mutations
  • The future treatment landscape for prostate cancer patients will likely include the earlier introduction of PARPi's and treatment beyond patients with HRR/DRR mutations
Image of Prof. Fred Saad
Prof. Fred Saad

Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer

University of Montreal Hospital Center, Canada

Canada

Portrait of Tanya Dorff
Assoc. Prof. Tanya Dorff

Medical Oncologist

City of Hope Comprehensive Cancer Center

United States (US)

Portrait of Gerhardt Attard
Prof. Gerhardt Attard

Medical Oncologist

University College London Cancer Institute

United Kingdom (UK)

Image of Neeraj Agarwal
Prof. Neeraj Agarwal

Medical Oncologist

University of Utah Huntsman Cancer Institute

United States (US)

preview next

Incorporating PARP inhibitors into prostate cancer clinical practice

time Event Experts Knowledge Share | open 78 min | Nov 2022

I agree that this educational programme:

Incorporating PARP inhibitors into prostate cancer clinical practice.

 

In this Expert Knowledge Share event, guest expert Prof. Fred Saad (Canada) joined GU CONNECT members Assoc. Prof Tanya Dorff (USA), Prof. Gerhardt Attard (UK) and Prof. Neeraj Agarwal (USA), and participants from around the world to discuss incorporating PARP inhibitors into prostate cancer clinical practice

GU CONNECT invites you to watch the on-demand video replay above and download the accompanying slide set. An accredited e-learning programme will follow shortly.

 

Video Chapters

Chapter 1  00:00     Scene-setting - Prof. Fred Saad

Chapter 2  05:23     Use of PARP inhibitors beyond the first-line setting in mCRPC - Prof. Fred Saad and Prof. Gerhardt Attard

Chapter 3  39:24     Use of PARP inhibitors in the first-line setting in mCRPC - Assoc. Prof. Tanya Dorff and Prof. Neeraj Agarwal

Chapter 4  1:09:50  Questions and panel discussion

Chapter 5  1:14:06   Future perspectives and summary - Prof. Fred Saad

This educational programme is supported by an Independent Medical Education Grant from AstraZeneca

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

Other programmes developed by Assoc. Prof. Tanya Dorff

Portrait of Tanya Dorff
Assoc. Prof. Tanya Dorff

Medical Oncologist

City of Hope Comprehensive Cancer Center

United States (US)

Other programmes developed by Prof. Gerhardt Attard

Other programmes developed by Prof. Neeraj Agarwal